Nationwide Recall Issued for ADHD Medication Lisdexamfetamine Dimesylate
Several lots of a generic version of the ADHD medication Vyvanse, Lisdexamfetamine Dimesylate, have been recalled nationwide due to failed lab tests, potentially impacting individuals managing attention-deficit/hyperactivity disorder.
Sun Pharmaceutical Industries Inc. initiated the recall on October 28, 2025, after discovering “Failed Dissolution Specifications,” meaning the capsules did not dissolve properly during quality control testing. The Food and Drug Administration (FDA) classified the recall as Class II on October 30, indicating that while use may cause temporary health consequences, the risk of serious adverse effects is considered remote. This follows a similar recall of a cholesterol medication last month, raising concerns about pharmaceutical quality control.
The recall affects 100-count bottles of Lisdexamfetamine Dimesylate in various strengths (10mg, 20mg, 30mg, 40mg, 50mg, 60mg, and 70mg) with the following lot numbers and expiration dates: AD42468 (Exp. 2/28/26), AD48705 (Exp. 4/30/26), AD42469 (Exp. 2/28/26), AD48707 (Exp. 4/30/26), AD42470 (Exp. 2/28/26), AD48708 (Exp. 4/30/26), AD48709 (Exp. 4/30/26), AD50894 (Exp. 5/31/26), AD48710 (Exp. 4/30/26), AD50895 (Exp. 5/31/26), AD48711 (Exp. 4/30/26), AD50896 (Exp. 5/31/26), AD48712 (Exp. 4/30/26), and AD50898 (Exp. 5/31/26). A complete list of recalled medications can be found on the FDA’s website.
Because no press release accompanied the recall, specific instructions for patients are unavailable. However, experts caution against abruptly stopping ADHD medication, as this can lead to withdrawal symptoms; individuals with affected bottles should consult their doctor or pharmacist for guidance. You can learn more about managing ADHD medication at the Centers for Disease Control and Prevention.
The FDA advises that patients can continue using the medication unless directed otherwise by the recalling company or the agency.
